UBTF tandem duplications (UBTF-TD) define a high-risk molecular subtype of acute myeloid leukemia (AML). Although menin inhibitors show therapeutic promise in UBTF-TD AMLs, acquired resistance remains a challenge. In this study, we used proteomic, epigenetic, and functional analyses to uncover mechanisms underlying UBTF-TD leukemogenesis. Biochemical studies showed that UBTF-TDs result in structural destabilization and create nuclear export signal (NES) motifs, which mediate direct interactions with exportin-1 (XPO1). In cord blood CD34+ UBTF-TD models, these interactions were shown to drive aberrant chromatin binding and transcriptional activation of genes dysregulated in UBTF-TD tumors. Through mutagenesis, we demonstrated that these NES motifs are critical for localization of UBTF-TD proteins to chromatin, transcriptional dysregulation, and cellular proliferation and differentiation. In preclinical UBTF-TD models of human leukemia, we found that XPO1 inhibition disrupts UBTF-TD chromatin localization, reduces tumor burden, and promotes differentiation. These mechanistic findings highlight XPO1 inhibition as a potential therapy for UBTF-TD AMLs. Significance: UBTF tandem duplications are a high-risk AML subtype. We identified a mechanism in which UBTF-TDs result in the generation of NES motifs, enabling aberrant interaction with XPO1. We found that XPO1 inhibitors block this interaction and impair leukemia growth, identifying a possible therapeutic strategy in UBTF-TD AML. See related commentary by Adams, p. 15
Illustrates chromatin protein interactions involving UBTF-TD54–NES-M in K562 cells using qPLEX-RIME. Panel A outlines the experimental design. Panels B and C present volcano plots comparing UBTF-TD54–NES-M to UBTF-WT and NES-M, respectively.
Flow cytometry analysis in UBTF-TD PDX models. (A) Gating strategy for peripheral blood and bone marrow used in Figures 6 and 7. (B–C) Representative plots and summary of peripheral blood chimerism following eltanexor treatment. (D–E) Representative flow cytometry plots from Figures 6D and 7E.
Eltanexor treatment in primary human cells. (A–B) Flow cytometry gating and representative plots related to Figures 5C–E. (C) CellTiter-Glo assay in CD34⁺ cells expressing UBTF-TD or UBTF-TD-NES-M. (D) HOXA/B gene expression heatmap after DMSO, dTAG-13, or eltanexor treatment. (E) UpSet plot showing UBTF-TD and XPO1 gene occupancy changes. (F–G) Design and results of colony-forming assays in UBTF-TD PDX cells treated with eltanexor.
Panel A shows western blot analysis (anti-HA) of cbCD34⁺ cell lysates transduced with various HA-tagged UBTF constructs and vector control. Panel B presents RNA-seq tracks visualized in IGV, highlighting soft-clipped reads that indicate tandem duplications and the expressed cDNA sequences. Panel D-F depict gating strategies and representative flow plots